Home › Research › Treatments
Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials
Schneider LS, Dagerman KS, Insel P.. JAMA, 2005-10-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Context Atypical antipsychotic medications are widely used to treat delusions, aggression, and agitation in people with Alzheimer disease and other dementia; however, concerns have arisen about the increased risk for cerebrovascular adverse events, rapid cognitive decline, and mortality with their use. Conclusions Atypical antipsychotic drugs may be associated with a small increased risk for death compared with placebo.
What this study adds
Evidence grade: High
This is a pooled review of 3,353 participants. This meta-analysis of randomized placebo-controlled trials found that atypical antipsychotic drugs, used for delusions, aggression, and agitation in people with dementia, may be associated with a small increased risk of death compared with placebo. Reported effect size: 3.5%; 2.3%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Schneider, L. S., Dagerman, K. S., & Insel, P. (2005). Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. https://doi.org/10.1001/jama.294.15.1934
Vancouver
Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005. doi:10.1001/jama.294.15.1934. PMID: 16234500.
BibTeX
@article{schneider2005-16234500,
author = {Schneider, L. S. and Dagerman, K. S. and Insel, P.},
title = {{Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials}},
journal = {JAMA},
year = {2005},
doi = {10.1001/jama.294.15.1934},
pmid = {16234500},
url = {https://doi.org/10.1001/jama.294.15.1934}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Context Atypical antipsychotic medications are widely used to treat delusions, aggression, and agitation in people with Alzheimer disease and other dementia; however, concerns have arisen about the increased risk for cerebrovascular adverse events, rapid cognitive decline, and mortality with their use.
- Conclusions Atypical antipsychotic drugs may be associated with a small increased risk for death compared with placebo.
Why it matters
This meta-analysis of randomized placebo-controlled trials found that atypical antipsychotic drugs, used for delusions, aggression, and agitation in people with dementia, may be associated with a small increased risk of death compared with placebo. It does not address treating, curing, or preventing Alzheimer's disease itself.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designmeta-analysis
- Participants3,353
- Effect size3.5%; 2.3%
- Evidence strengthHigh
How this study scored 82/100
Published in a top-tier journal, and it is a meta-analysis pooling many studies.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (JAMA) |
| Journal's citation record | 4 / 4 | JAMA: journal h-index 1,011 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A meta-analysis pooling many studies |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2005 — older than 20 years, still counted |
| Sample size | 3 / 4 | 3,353 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | 7 / 7 | Cited 1,672 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 72.7 citations a year over 23 year(s) since 2005 |
| Impact for its field and year | 6 / 6 | Cited 58.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 36 other studies in this library |
| Still being cited | 3 / 4 | Cited 130 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Philip S. Insel: h-index 50 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Southern California: institution h-index 1,521 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 16234500) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 82 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
36 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.